Podium to Practice: ESMO® 2026 – Breast: JCOG1204A1
OR
Studies / Trials Discussed
542RO – Prognostic impact of postoperative ctDNA surveillance on relapse-free survival and molecular lead time in high-risk breast cancer: JCOG1204A1
Explore more from your favourite experts – click their name to access their entire library of content.
This program has been made possible through unrestricted support from Novartis.
Studies/trials discussed:
542RO – Prognostic impact of postoperative ctDNA surveillance on relapse-free survival and molecular lead time in high-risk breast cancer: JCOG1204A1
Login to view content
PLease Enter Your Email to view Content
Pre-Video Survey
By continuing to watch the video, you consent to receiving a post-view survey by email.